Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 29, 2018

View Archived Issues

CHMP grants positive opinion for labeling update to Relvar Ellipta in patients with asthma

CHMP supports approval of Shingrix for prevention of shingles in adults aged 50 and over

First patient dosed in phase II study of MCLA-128 in breast cancer

Adocia reports topline results from phase Ib study of BioChaperone Combo

FDA approves Lutathera to treat gastroenteropancreatic neuroendocrine tumors

Reolysin induces robust immune responses in patients with metastatic colorectal cancer

Sanofi set to acquire Ablynx

Survival data presented for patients with pancreatic cancer under CCX-872 therapy

Merck Sharp & Dohme initiates phase I study of MK-4250 in ART-naive patients with HIV-1

EMA committee recommends approval of Hemlibra in hemophilia A

FDA grants fast track designation to Traumakine for ARDS

Clinical activity seen with encorafenib/binimetinib/cetuximab treatment in BEACON CRC trial

Amgen explores use of AMG-757 in small cell lung cancer

Phase I clinical data presented for E-7046 in patients with solid tumors

Bioniz begins phase I/II study of BNZ-1 in LGL leukemia and refractory CTCL

Acquist patents novel SLC22A12 inhibitors

Guangzhou Maxinovel Pharmaceuticals discloses PD-1 signaling inhibitors

Blade Therapeutics identifies new calpain inhibitors

Daewoong Pharmaceutical divulges new BTK inhibitors

Bristol-Myers Squibb presents novel ROCK2 inhibitors

Novartis' branaplam given FDA orphan drug status for spinal muscular atrophy

EMA committee hands down negative opinion for enclomiphene MAA

RaQualia and ZTE Coming Biotech sign joint cooperation agreement

Novel compounds validate nicotinamide-N-methyltransferase as an antiobesity target

NIH initiates phase III trial of antiretroviral regimens in pregnant women with HIV

American Gene Technologies makes progress towards phase I study of HIV functional cure product

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...